Back to News
May 21, 2026 4:00 PM

BioMarin Reveals Dwarfism Study Data, Stock Soars

BioMarin Pharmaceuticals Inc. (NASDAQ:BMRN) stock is trading higher on Thursday as the company is celebrating positive results from its Phase 3 CANOPY-HCH-3 study for VOXZOGO (vosoritide) in children with hypochondroplasia.

Hypochondroplasia is a form of genetic, short-limbed dwarfism.

The study met its primary endpoint, showing a statistically significant improvement in annualized growth velocity compared to placebo, which has excited investors and analysts alike.

Read Also:

BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients

VOXZOGO Study Meets Primary Endpoint

The CANOPY-HCH-3 study demonstrated a 2.33 cm/year increase in annualized growth velocity at week 52, significantly exceeding expectations.

With plans for a supplemental New Drug Application submission to the FDA in the third quarter of 2026, these results could pave ...